Objectives: The development of endometriosis is associated with changes in the expression of genes encoding the 3β-hydroxysteroid dehydrogenase type II (HSD3B2) and 17β-hydroxysteroid dehydrogenase type II (HSD17B2), estrogen receptors 1 (ESR1) and 2 (ESR2) and the androgen receptor (AR). However, little is known about the expression of HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR during the endometrial phases in eutopic endometrium from infertile women with endometriosis.
INTRODUCTION
Endometriosis is a disease characterized by the existence of functional ectopic endometrium outside the uterine cavity that affects 6-10% of women of reproductive age [1] . Three main etiopathogenic hypotheses regarding the development of endometriosis have been suggested [2, 3] . The most widely accepted includes the retrograde shedding of endometriotic cells during menstruation inside the abdominal cavity, which results in a persistent inflammatory response [2, 3] . Other theories explaining the development of these lesions include the coelomic metaplasia theory, which relates to the formation of endometrial tissue from the differentiation of mesothelium cells [2, 3] . It has also been suggested that there is an embryonic origin of endometriosis [2, 3] . Depending on the severity of endometriosis, it can be subdivided into peritoneal, ovarian and deep lesions, which spread in the vagina, bowels, bladder or ureter [4, 5] . Endometriosis is a complex disorder resulting from interactions between genetic and environmental factors [6, 7] . The development of endometriosis is related to the abnormal expression of genes encoding proteins involved in vascular and tissue remodelling, enzymes involved in www. journals.viamedica.pl/ginekologia_polska glucose homeostasis and proteins affecting sex hormone activity [6, 8] . Endometriosis is also characterized by epigenetic disorders associated with the hypermethylation and hypomethylation of some gene promotors, modifications of the histone code and abnormal expression of various miRNAs involved in the pathogenesis of this disease [9] .
However, the exact molecular mechanism accounting for the development of endometriosis and related infertility remains unclear [3] . To date, the expression of several genes involved in the metabolism and action of steroids have been demonstrated as being involved in endometriosis [10] [11] [12] [13] . They include genes encoding 3β-hydroxysteroid dehydrogenase (HSD3B2) (OMIM * 613890), 17β-hydroxysteroid dehydrogenase type I (HSD17B1) (OMIM * 109684), 17β-hydroxysteroid dehydrogenase type II (HSD17B2) (OMIM * 109685), estrogen receptor 1 (ESR1) (OMIM +133430), estrogen receptor 2 (ESR2) (OMIM * 601663), and androgen receptor (AR) (OMIM * 313700). However, little is known about HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in luteal and follicular eutopic endometrium in infertile women with endometriosis. Therefore, we assessed the expression of these genes during the follicular and luteal phases in eutopic endometrium from infertile women with endometriosis and fertile women.
MATERIAL AND METHODS

Patients and controls
Data from fertile women and infertile women with endometriosis were randomly collected from the Gynaecologic and Obstetrical University Hospital, Division of Reproduction in Poznan, Poland (Tab. 1). The control group comprised fertile women who suffered from chronic pelvic pain, diagnosed as having varicose veins in the pelvic floor without any pelvic abnormalities and without a history of infertility.
The varicose veins in the pelvic floor were diagnosed by ultrasound method and confirmed via laparoscopy. The criteria for the sonographic diagnosis of varices included (1) the visualization of dilated ovarian veins greater than 4 mm in diameter, (2) dilated tortuous arcuate veins in the myometrium that communicate bilaterally with the pelvic varicose veins, (3) slow blood flow (less than 3 centimeters per second), and reversed caudal or retrograde venous blood flow particularly in the left ovarian vein [14] .
The inclusion and exclusion criteria for the women without endometriosis and the infertile women with endometriosis were previously described [15] . During laparoscopy, we observed the condition of the pelvic cavity, uterus, fallopian tubes, ovaries, tubo-ovarian relationship, status of the Pounch of Douglas, and fimbrie. The inclusion criteria for the fertile control women were: regular menses, mobility of uterus, no anatomical changes in the reproductive tract, no hormonal treatments, and at least one child born no more than one year before the study (Tab. 1). The exclusion criteria were: signs of past or present inflammation. We didn't find inflamed fallopian tubes. In each patient, the peritoneal fluid was sampled for bacteriological examination, and was found to be sterile. Exclusion criteria also included pelvic abnormalities such as uterine fibroids, ovarian cysts, hydrosalpinges, adhesions in pouch of Douglas and the rest of the pelvis, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS) or any other benign or malignant gynaecological diseases.
Patients with endometriosis were evaluated according to the revised American Society for Reproductive Medicine (rASRM) classification system [16] (Tab. 1). The inclusion criteria for infertile women with diagnosed endometriosis were: regular menses, no anatomical changes in the reproductive tract, no hormonal treatments and a minimum of one year of [17] . Samples of mid-luteal eutopic endometrium tissue from patients and controls were collected during the implantation window, i.e., 7-9 days after ultrasound-confirmed ovulation. The eutopic endometrium samples were then used for total RNA and protein isolation.
Reverse transcription and quantitative real-time PCR (RT-QPCR) analysis of HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcript levels
The obtained endometrial samples were placed overnight in Allprotect Tissue Reagent Solution (Qiagen GmbH, Hilden, Germany) and frozen until extraction. Isolation of total RNA containing cytoplasmic mRNA was conducted with the use of the AllPrep DNA/RNA/Protein Mini Kit (Qiagen GmbH, Hilden, Germany). For total RNA isolation we used, according to the manufacturer recommendation, an additional RNase-Free Dnase I Set (Qiagen GmbH, Hilden, Germany) to eliminate the risk of DNA contamination. RNA quality was determined spectrophotometrically using a NanoDrop ND1000 (Thermo Fisher Scientific, Waltham, MA) and agarose gel electrophoresis. RNA samples were reverse-transcribed (RT) into complementary DNA (cDNA) with the Quanti-Tect Reverse Transcription Kit (Qiagen GmbH, Hilden, Germany) (Tab. 2).
Quantitative analysis of HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR cDNAs (Tab. 2) was performed by the Rotor-Gene 3000 thermocycler (Corbett Research, Australia), using SYBR Green I as the detection dye. HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR cDNAs were quantified using the relative quantification method with a calibrator. The calibrator was prepared with a cDNA mix from all cDNA samples, and consecutive dilutions were used to create a standard curve. For amplification, 1 μl of the cDNA solution was added to 19 μl of the DyNAmo HS SYBR Green qPCR Kit (Thermo Fisher Scientific, Waltham, MA) and primers mix (Tab. 2). The HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR transcript levels in each sample were standardized by the geometric means of the reference beta-actin (ACTB) and ribosomal protein stalk subunit P0 (RPLP0) transcript levels. The PCR amplification efficiency for the target and reference cDNA was determined by different standard curves created by consecutive dilutions of the cDNA template mixture. The HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR cDNA and ACTB and RPLP0 cDNAs were amplified using the primer pairs presented in Table 2 . The HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR mRNA levels were expressed as multiples of these cDNA concentrations in the calibrator. The Y axis presents relative quantity (RQ) of HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR mRNA levels.
Data analysis
Statistical analyses were conducted using the Mann--Whitney rank sum test and the Kruskal-Wallis one-way ANOVA on ranks. Statistical analyses were conducted using Statistica version 10, 2011 (Stat Soft, Inc., Tulsa, USA).
Ethics
The study was conducted in accordance with the code of ethics of the Declaration of Helsinki and obtained the approval of the Local Ethical Committee of Poznan University of Medical Sciences (923/14/04.12.2014). Written informed consent was obtained from all participating individuals.
RESULTS
Comparison of HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcript levels in the mid-follicular eutopic endometrium between infertile women with endometriosis and fertile women
The biopsy of eutopic endometrium was performed during the mid-follicular phase in 10 infertile women with endometriosis at I/II severity stage and 10 infertile women with III/IV severity stage. The biopsy of eutopic endometrium was also performed in 9 healthy fertile women during the mid-follicular phase (Tab. 1).
In the mid-follicular eutopic endometrium, we observed a significant increase in HSD3B2 transcript levels in all infertile women with endometriosis (p = 0.003) and in patients with stage I/II endometriosis (p = 0.008) and stage III/IV endometriosis (p = 0.009) compared to the levels in all fertile women (Fig. 1A ). There were no significant differences in HSD17B1 transcript levels between all infertile women with endometriosis (p = 0.899), subgroups with stages I/II endometriosis (p = 0.222) and stages III/IV endometriosis (p = 0.625) and fertile women (Fig. 1B) . We found an increasing trend in HSD17B2 transcript levels, which was not statistically significant, in the mid-follicular eutopic endometrium in all infertile women with endometriosis (p = 0.071). We found a significantly increased HSD17B2 transcript level in the subgroup of patients with stages I/II endometriosis (p = 0.029) but not in the stages III/IV subgroup (p = 0.351) (Fig. 1C) . We observed a significant increase in ESR1 transcript levels in all infertile women with endometriosis (p = 0.008), those with stages I/II endometriosis (p = 0.019) and those with stages III/IV endometriosis (p = 0.023) compared to the level in all fertile women (Fig. 1D) . There was no significant increasing trend of ESR2 transcript levels in the mid-follicular eutopic endometrium in all infertile women (p = 0.079) with endometriosis, or in subgroups with stages I/II (p = 0.056) and III/IV (p = 0.261) compared to the levels in fertile women (Fig. 1E) . We did not find significant differences in AR transcript levels between all infertile women with endometriosis (p = 0.461) or subgroups with stages I/II (p = 0.450) and III/IV (p = 0.635) and fertile women (Fig. 1F) .
Comparison of HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcript levels in the mid-luteal eutopic endometrium between infertile women with endometriosis and fertile women
The biopsy of eutopic endometrium was performed during the mid-luteal phase in 8 infertile women with endometriosis at I/II severity stage and 7 with III/IV severity stage. The biopsy of eutopic endometrium was also was performed in 8 healthy fertile women during the mid-luteal phase (Tab. 1).
In the mid-luteal eutopic endometrium, we found a statistically insignificant increasing trend of HSD3B2 transcript levels in all infertile women with endometriosis (p = 0.057) and in the subgroups with stages I/II (p = 0.055) but not in the subgroup with stages III/IV (p = 0.225) when compared to the levels in fertile women ( Fig. 2A ). There were no significant differences between fertile women and all infertile women with endometriosis, the subgroup with stages I/II and the subgroup with stages III/IV for transcript levels of (Fig. 2B-2F ).
DISCUSSION
Endometriosis is an estrogen-influenced gynaecological disorder characterized by over-activity of the estrogen pathway, including increased production of 17-bestradiol (E2) and its action in the eutopic and ectopic endometrium.
HSD3B catalyses the oxidation and isomerization of d-5-3-beta-hydroxysteroid precursors into delta-4-ketosteroids resulting in the formation of all classes of steroids. The HSD3B also converts epiandrosterone, to 5α-androstan-3--one. HSD3B1 is expressed predominantly in the placenta and the skin, whereas HSD3B2 is expressed almost exclusively in the adrenal glands and the gonads [18] . To date there have been several studies that evaluated HSD3B2 expression in endometriosis [10] [11] [12] . Attar et al. (2009) demonstrated that HSD3B2 transcript levels are significantly upregulated in extraovarian (peritoneal) endometriotic tissues compared to eutopic endometrial tissue from endometriosis-free women [10] .
It has also been found that interleukin-4 and prostaglandin E2 synergistically increased HSD3B2 transcript levels in endometrioma stromal cells [11] . Frozen tissue was homogenized, followed by total RNA isolation. Quantitative analyses of transcript levels were performed by RT-qPCR using the SYBR Green I system. The HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcript levels in each sample were standardized by the geometric mean of references using ACTB and RPLP0 cDNA levels. The P value was evaluated by the Mann-Whitney rank sum test and the Kruskal-Wallis test with pairwise multiple comparisons and post hoc Dunn's test. The boxes and the middle lines correspond to the values from the lower to upper quartiles and the medians, respectively. RQ-relative quantity Frozen tissue was homogenized, followed by total RNA isolation. Quantitative analyses of transcript levels were performed by RT-qPCR using the SYBR Green I system. The HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcript levels in each sample were standardized by the geometric mean of references using ACTB and RPLP0 cDNA levels. The P value was evaluated by the Mann-Whitney rank sum test and the Kruskal-Wallis test with pairwise multiple comparisons and post hoc Dunn's test. The boxes and the middle lines correspond to the values from the lower to upper quartiles and the medians, respectively. RQ-relative quantity found any differences in HSD3B2 transcript levels between luteal and follicular phase eutopic endometrium from women with endometriosis and the eutopic endometrium of healthy women [12] . In our studies we found significantly increased levels of HSD3B2 transcript in the mid-follicular eutopic endometrium from all infertile women with endometriosis and in subgroups with stages I/II and III/IV when compared to the transcript levels in healthy women. In contrast, in the mid-luteal phase, there was no significant increasing trend of HSD3B2 transcripts in all infertile women with endometriosis or in the subgroup with stages I/II versus the levels in the controls.
The presence of HSD17B1 and HSD17B2 oxidoreductases has been demonstrated in the eutopic endometrium [13] . HSD17B1 oxidizes estrone (E1) to E2, which is a more biologically active estrogen, while HSD17B2 reduces E2 to E1 [19] . Smuc et al. (2007) reported significantly increased HSD17B1 transcript levels in ectopic ovarian endometriosis compared to the levels in normal eutopic endometrium [13] . Delvoux et al. (2013) demonstrated that inhibition of HSD17B1 can potentially be used as a treatment to restore the correct metabolism of estrogen in women with endometriosis with elevated local HSD17B1 activity [19] . However, in our study we did not find differences in HSD17B1 transcript levels between the eutopic endometrium of fertile women and that of infertile women with endometriosis.
Expression of HSD17B2 in the luteal phase is upregulated by progesterone in the endometrial glandular cells converting E2 to E1, the less biologically active estrogen [20] . Deficiency of the HSD17B2 enzyme impairs the inactivation of E2 to E1, which favours the accumulation of E2 in endometriosis [21] . Zeitoun et al. (1998) demonstrated the presence of HSD17B2 transcripts and proteins in the luteal eutopic endometrium of healthy women but not in the luteal samples of endometriotic lesions [22] . Smuc et al. (2007) reported significantly decreased HSD17B2 transcript levels in ectopic ovarian endometriosis compared to normal endometrium [13] and HSD17B2 deficiency and locally increased E2 levels in ectopic implants in endometriosis [23] . In our studies, we found a statistically insignificant increasing trend of HSD17B2 transcript levels in the eutopic endometrium during the follicular phase but not in the luteal phase.
The estrogen receptor exists in two isoforms: ESR1 and ESR2 [24] [25] with a 56% homology between them [26] . ER activity depends on the binding of E2 and the nuclear receptor-induced transcription of ER-regulated genes. Research in the murine model has demonstrated that ESR1 plays the primary role in the uterus and neuroendocrine system, and female mice lacking ESR1 are infertile because of impaired ovarian and uterine function, while those lacking ESR2 display ovarian defects and subfertility [27] . The abnormal expression of ESR1 has been reported in endometriosis [13, 28, 29] . Smuc et al. (2007) demonstrated that ESR1 transcript levels were downregulated in women with endometriosis group compared to the levels in the control group [13] . Using chromatin immunoprecipitation analysis, Monteiro et al. (2012) revealed the hypoacetylation of H3/H4 histones inside the ESR1 promoter in endometriosis lesions but not in the control eutopic endometrium [28] . This hypoacetylation of H3/H4 accounted for reduced ESR1 expression in endometriosis lesions versus control eutopic endometrium [28] . Recently, Khan et al. (2017) suggested dysregulation of ESR1 expression as one of the significant causative factors in the pathogenesis of ovarian endometriosis [29] In our studies, we observed a significant increase in ESR1 transcript levels in the follicular but not the luteal phase in all infertile women with endometriosis and in the subgroups with stages I/II and stages III/IV.
The knowledge of biologic roles of ESR2 in the endometrium and in endometriosis is still elusive [30] . Smuc et al. (2007) demonstrated that ESR2 transcript levels were upregulated in the endometriosis group versus the control group [13] . An ESR2-selective compound has been demonstrated to have therapeutic activity in a rodent endometriosis model [30] . Our study only demonstrated an insignificant increase in ESR2 transcript levels in the mid-follicular eutopic endometrium in all infertile women with endometriosis and in the subgroup with stages I/II.
To date, AR gene CAG repeat polymorphisms have been associated with an increased risk for mild endometriosis [31] . However, our results did not reveal any significant changes in the expression of AR in the proliferative and luteal phases between infertile women with endometriosis and fertile women.
The differences between our results and others in terms of expression might be due to the employment of ectopic implants, despite the eutopic endometrium of endometriosis. Studies usually compare the expression of genes encoding proteins involved in estrogen activity in ectopic implants of endometriosis independent of the menstrual cycle phases [10-13, 22, 23, 28, 29] . We conducted our study using primary eutopic endometrium consisting of a mix of uterine gland, columnar epithelium and stromal fibroblast cells. Our study was also conducted in selected infertile women with endometriosis with determined menstrual phase cycles. However, our study has limitations with the very small number of studied cases and needs further evaluation of proteins using either immunohistochemistry or western blot.
CONCLUSIONS
Observed significant increase in HSD3B2 and ESR1 transcripts in follicular eutopic endometrium from infertile women with endometriosis may be related to abnormal
